Lesson plan
MN-25
MN-25 (UR-12) is a drug invented by Bristol-Myers Squibb, that acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB 2 receptors with a K i of 11 nM, but 22x lower affinity for the psychoactive CB 1 receptors with a K i of 245 nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a K i of 8 nM at CB 1 and 29 nM at CB 2 , which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB 2 (cf. JWH-018 vs JWH-007, JWH-081 vs JWH-098). Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, Org 28611, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in JWH-200 or A-796,260. Early compounds such as these have subsequently led to the development of many related indole-3-carboxamide cannabinoid ligands.
Article summary
MN-25 (UR-12) is a drug invented by Bristol-Myers Squibb, that acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB 2 receptors with a K i of 11 nM, but 22x lower affinity for the psychoactive CB 1 receptors with a K i of 245 nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a K i of 8 nM at CB 1 and 29 nM at CB 2 , which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB 2 (cf. JWH-018 vs JWH-007, JWH-081 vs JWH-098). Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, Org 28611, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in JWH-200 or A-796,260. Early compounds such as these have subsequently led to the development of many related indole-3-carboxamide cannabinoid ligands.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.